Treatment

Vosoritide therapy in children with achondroplasia aged 3βˆ’59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial
·

Vosoritide therapy in children with achondroplasia aged 3βˆ’59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial

Source: The Lancet Child & Adolescent Health Authors: Prof Ravi Savarirayan, MD β€’ Prof William R Wilcox, MD β€’ Prof Paul Harmatz, MD β€’ John Phillips III, MD β€’ Lynda…